Diagnostic Expansion in Clinical Trials: Myocardial Infarction, Stroke, Cancer Recurrence, and Metastases May Not be the Hard Endpoints you Thought They Were
21 Sep, 2018 | 02:00h | UTCDiagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were – The BMJ (free for a limited period)